How I Treat Elderly AML Patients in 2021: Does Midostaurin Improve OS in FLT3m Disease? Are DA+Cytarabine+/-GO Beneficial for EFS in Untreated Patients? Is CPX-351 Better Than SoC Chemo?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

How I Treat Elderly AML Patients in 2021: Does Midostaurin Improve OS in FLT3m Disease? Are DA+Cytarabine+/-GO Beneficial for EFS in Untreated Patients? Is CPX-351 Better Than SoC Chemo?

By 3rd Annual Hematologic Malignancies Symposium FEATURING Gail G. Roboz

119 views

April 8, 2021

0 Comments

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

ASH 2023 Summary: "The Best of Acute Leukemia and MDS - Highlig…

Feat. T. Badar

21:05

Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale

50:34

Scripps MD Anderson Cancer Center

The Cure of Leukemias in the Next Decade: An Optimist’s View

Feat. H. Kantarjian

19:10

5th SOHO Italy Annual Conference

SOHO Italy 2023: How I Treat AML at MD Anderson Cancer Center

Feat. H. Kantarjian

12:36

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Myeloid for Measure - New Therapeutics in…

Feat. A. Patel

09:51

i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje

12:33

SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: AML

Feat. H. Kantarjian

14:19

Talha Badar

Challenges in the Management of TP53-Mutated AML: Potential Strategi…

44:26

University of Colorado Division of Hematology

Novel Therapies in AML and MDS

Feat. D. Pollyea

14:39

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Immunotherapies in Acute Leukemias: 2024 Update

Feat. C. Lai

22:30

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Emerging Treatment Options for AML in 2024

Feat. A. Perl

13:39

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Triplet Regimens in AML: Beyond Azacitidine + Venetoclax

Feat. C. DiNardo

27:28

UChicago Medicine

AML: Current Treatment Landscape and Key Recent Updates

Feat. A. Patel

12:28

Roswell Park Comprehensive Cancer Center

Current Landscape of R/R AML Treatment

Feat. E. Wang

02:52

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Results From a Phase 1 Clinical Study of …

Feat. M. Amaya

32:04

Moffitt Cancer Center

Experts Discuss the Latest Data in Myeloid Diseases

Feat. A. Kuykendall, R. Komrokji, O. Chan, D. Sallman

40:21

Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Overview of Hematopoietic Cell Transplantation

Feat. R. Salit

15:45

SOHO 2022 Tenth Annual Meeting

SOHO 2022: How Do We Overcome Resistance to Venetoclax in AML

Feat. M. Konopleva

16:59

MyCancerHaven

Experts Discuss Current and Future Management of AML

Feat. R. Vij, N. Daver

18:48

Current Challenges in Hematology

Venetoclax-Based Combinations in Newly Diagnosed AML: A New Golden S…

Feat. C. DiNardo

Login

Login

Join VuMedi

How I Treat Elderly AML Patients in 2021: Does Midostaurin Improve OS in FLT3m Disease? Are DA+Cytarabine+/-GO Beneficial for EFS in Untreated Patients? Is CPX-351 Better Than SoC Chemo?

Related Content